BioArctic collaborator Novartis terminates agreement
PR Newswire•02/11/2026•16:14 ET
0
Key Highlights
- ➤Novartis terminates August 2025 collaboration to explore a BrainTransporter-based treatment
- ➤BioArctic retains the full USD 30 million upfront payment
- ➤BioArctic will recognize the remaining unrecognized payment as 2026 revenue
- ➤Novartis discontinued the program for reasons unrelated to BrainTransporter technology
BioArctic collaborator Novartis terminates agreement PR Newswire
STOCKHOLM, Nov. 2, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that Novartis Pharma AG has notified BioArctic that it has decided to terminate the Option, Collaboration and License Agreement entered into in August 2025 to explore a potential new treatment combining BioArctic's proprietary BrainTransporter™ technology with an undisclosed Novartis proprietary antibody.
Get started
Create a free account to read the full story.